title: Combination therapy for HIV: the effect on inpatient activity, morbidity and mortality of a cohort of patients.
abstract: We set out to quantify the changes in HIV-related morbidity and mortality associated with the clinical use of antiretroviral therapy via prospectively collected patient-related events (admissions, bed days, deaths, WHO stage 3 and 4 events and drug costs) on all HIV patients known to the Regional Infectious Disease Unit (RIDU) from 1 January 1987 to 31 December 1996. The introduction of zidovudine monotherapy in 1987 for those with AIDS was associated with a subsequent decline of inpatient activity for 2 years: in 1989 there was a 23% reduction in bed days but only a 6% reduction in admissions. A further dramatic decline of patient-related events in those with AIDS was noted during 1996 following the introduction of combination therapy, a 39% reduction in admissions, 44% reduction in bed days, 54% reduction in stage 4 events, 33% reduction in WHO stage 3 events and 40% reduction in the death rate. Reductions were also observed for patients without AIDS including a 42% reduction in the rate of patients developing AIDS. Similar reductions were noted when the patients were classified by immunological instead of clinical status although data for 1997 suggest an increase in patient-related activity for those with CD4 counts >200 cells/microl possibly as a result of low levels of anti-HIV therapy. The introduction of combination therapy for HIV has to date led to a minimum saving of one inpatient bed per 100 patient years which helped defray the cost of combination therapy. Although we cannot imply causality from an observational study, dramatic reductions in patient-related activity were associated with the introduction of combination therapy into clinical practice. The ultimate extent and duration of this effect cannot as yet be predicted and caution is required since similar reductions were noted with zidovudine therapy which were unfortunately time limited.
authors.affiliation: Regional Infectious Disease Unit, City Hospital, Edinburgh, UK.
authors.forename: R P
authors.initials: RP
authors.lastname: Brettle
authors.forename: A
authors.initials: A
authors.lastname: Wilson
authors.forename: S
authors.initials: S
authors.lastname: Povey
authors.forename: S
authors.initials: S
authors.lastname: Morris
authors.forename: R
authors.initials: R
authors.lastname: Morgan
authors.forename: C L
authors.initials: CL
authors.lastname: Leen
authors.forename: S
authors.initials: S
authors.lastname: Hutchinson
authors.forename: S
authors.initials: S
authors.lastname: Lewis
authors.forename: S
authors.initials: S
authors.lastname: Gore
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D017046:Cost Savings; D003365:Costs and Cost Analysis; D016049:Didanosine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000276:immunology / Q000401:mortality; D006801:Humans; D011446:Prospective Studies; D016047:Zalcitabine / Q000627:therapeutic use*; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine